12
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9920 | Evolocumab | Others | |
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). | |||
T9276 | SBC-115337 | Others , Serine/threonin kinase | |
SBC-115337 is a PCSK9 inhibitor. | |||
T67776 | PCSK9-IN-11 | Others | |
PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity. PCSK9-IN-11 shows inhibitory activity of PCSK9 transcription in HepG2 cells (IC50= 5.7 μM). PCSK9-IN-11 can increase LDL receptor (LDLR) protein l... | |||
T72025 | PCSK9-IN-10 | Serine/threonin kinase | |
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Li... | |||
T5S0053 | Coptisine | Coptisin | Indoleamine 2,3-Dioxygenase (IDO) |
1. Coptisine (Coptisin) treatment increases cell viability based on its reversal effect on the enhanced activity of Indoleamine 2, 3-dioxygenase . 2. Coptisine treats myocardial I/R likely through suppressing myocardial ... | |||
T74577 | Milpocitide | ||
Milpocitide, a (293-333)-peptide fragment of the human low-density lipoprotein receptor (LDLR), specifically corresponds to the EGF-like domain 1 [1]. | |||
T15561 | Imanixil | HOE-402(free base) | Others |
Imanixil is an inducer of the LDL receptor (LDLR) and it is also a potent cholesterol-lowering compound. It also inhibits very low density-lipoprotein (VLDL) production and consequently decreases atherosclerosis developm... | |||
T81535 | PCSK9-IN-20 | ||
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor exhibiting an IC50 value of 3.96 µM, shown to reduce PCSK9 and enhance LDLR protein levels in vitro [1]. | |||
T39528 | PCSK9-IN-2 | PCSK9-IN-2 | |
PCSK9-IN-2 is a newly developed small molecule that effectively inhibits the protein-protein interaction (PPI) between PCSK9 and LDLR. It has been found to have a potent inhibitory activity with an IC50 value of 7.57 μM. | |||
T77014 | Frovocimab | ||
Frovocimab (LY 3015014), a humanized IgG4 monoclonal antibody (mAb), acts by neutralizing PCSK9. This mechanism effectively prevents PCSK9 from binding to the LDL receptor (LDLR) while allowing for the normal proteolytic... | |||
T78718 | Dim16 | ||
Dim16, a dual inhibitor of PCSK9/HMG-CoAR, demonstrates potent activity with an IC50 of 19 nM against PCSK9 and significantly impedes PCSK9-LDLR interaction with an IC50 of 0.8 nM, leading to an enhanced LDL uptake in He... | |||
T78806 | PPARδ agonist 9 | PPAR | |
PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic development in the LDLr-KO model with an inhibition rate of... |